Compare Abeona Therapeutics Inc (ABEO) vs iShares MSCI Japan ETF (EWJ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs iShares MSCI Japan ETF — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while iShares MSCI Japan ETF trades at $92.11. Which is the better fit depends on your goals.
| ABEO | EWJ | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $7.23 | $96.97 |
52-Week Low | $4.17 | $71.69 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
EWJ, the iShares MSCI Japan ETF, trades at $95.27, up 2.29% on the day, with a bullish technical signal driven by moving averages. The ETF provides exposure to Japanese equities, with recent news highlighting yen volatility and strong export data. Key support is at $94, with resistance at $96. A dividend of $0.50 is scheduled for June 2026.
Outlook remains tied to Japan's economic trends and currency dynamics. Opportunities include AI-driven export growth, but risks involve yen weakness and geopolitical tensions. Investors should weigh Japan's monetary policy shifts and global market sentiment for directional cues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About iShares MSCI Japan ETF
EWJ tracks the MSCI Japan Index, providing broad exposure to over 180 large and mid-cap companies in Japan. It is the most established and liquid vehicle for accessing the Japanese equity market, featuring a diversified portfolio across industrials, consumer discretionary, and financial sectors.
Read more on EWJ →
